SAN FRANCISCO, Dec. 8, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NasdaqGM:IMMU - News), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that low doses of veltuzumab, administered either intravenously or subcutaneously, demonstrated promising activity, including durable complete responses, in patients with immune thrombocytopenic purpura (ITP). Results from this multicenter, open-label, single-arm Phase I/II study were presented at the 50th American Society of Hematology annual meeting.
